New drug aims to save Insulin-Making cells in type 1 diabetes

NCT ID NCT06812988

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests brivekimig, a drug that targets inflammation, to see if it can help people with newly diagnosed type 1 diabetes keep making their own insulin. About 84 adults and adolescents will receive either brivekimig or a placebo for 52 weeks. The main goal is to measure insulin production after 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brivekimig (a dual anti-TNF-α and anti-OX40L antibody-like molecule)
What this could lead to: If successful, brivekimig could help people with newly diagnosed type 1 diabetes keep making some of their own insulin, reducing their dependence on injected insulin.
What could go wrong: This is an early Phase 2a trial with only 84 participants, so results may not apply to everyone. The drug may not preserve insulin production better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES MELLITUS

Contacts and locations

Locations

Advanced Research Institute - Odgen- Site Number : 8400007

Ogden, Utah, 84405, United States
Atlanta Diabetes Associates- Site Number : 8400006

Atlanta, Georgia, 30318, United States
Centro de Diabetes Curitiba- Site Number : 0760005

Curitiba, Paraná, 80810-040, Brazil
Centro de Pesquisas Clínicas - São Paulo- Site Number : 0760002

São Paulo, 01228-200, Brazil
IACT Health - Columbus - Talbotton Road- Site Number : 8400012

Columbus, Georgia, 31904, United States
Investigational Site Number : 0320001

Buenos Aires, 1119, Argentina
Investigational Site Number : 0320002

Buenos Aires, 1178, Argentina
Investigational Site Number : 0320003

Salta, 4400, Argentina
Investigational Site Number : 0320004

Buenos Aires, 1419, Argentina
Investigational Site Number : 0320005

Buenos Aires, 1180, Argentina
Investigational Site Number : 0360001

Parkville, Victoria, 3050, Australia
Investigational Site Number : 0360002

Brisbane, Queensland, 4029, Australia
Investigational Site Number : 0360003

Saint Leonards, New South Wales, 2065, Australia
Investigational Site Number : 1240001

Vancouver, British Columbia, V5Y 3W2, Canada
Investigational Site Number : 1240006

Surrey, British Columbia, V3T 2V6, Canada
Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, 7500505, Chile
Investigational Site Number : 1520003

Providencia, Reg Metropolitana de Santiago, 7500000, Chile
Investigational Site Number : 1520004

Concepción, Biobio, 4070566, Chile
Investigational Site Number : 3760001

Jerusalem, 9112001, Israel
Investigational Site Number : 3760002

Ramat Gan, 5262100, Israel
Investigational Site Number : 3760003

Kefar Sava, 4428164, Israel
Investigational Site Number : 6820002

Riyadh, 12713, Saudi Arabia
Profound Research - MHP - TriAtria- Site Number : 8400015

Farmington Hills, Michigan, 48334, United States
Tekton Research - McKinney- Site Number : 8400017

McKinney, Texas, 75069, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.